- Home
- KPRX vs AQMS Comparison
KPRX vs AQMS Comparison
Compare KPRX & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- AQMS
- Stock Information
- Founded
- KPRX 1998
- AQMS 2014
- Country
- KPRX United States
- AQMS United States
- Employees
- KPRX N/A
- AQMS 11
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AQMS Metal Fabrications
- Sector
- KPRX Health Care
- AQMS Industrials
- Exchange
- KPRX Nasdaq
- AQMS Nasdaq
- Market Cap
- KPRX 9.2M
- AQMS 24.2M
- IPO Year
- KPRX N/A
- AQMS 2015
- Fundamental
- Price
- KPRX $2.52
- AQMS $9.78
- Analyst Decision
- KPRX Strong Buy
- AQMS Buy
- Analyst Count
- KPRX 1
- AQMS 1
- Target Price
- KPRX $10.00
- AQMS $12.00
- AVG Volume (30 Days)
- KPRX 52.9K
- AQMS 5.2M
- Earning Date
- KPRX 11-07-2025
- AQMS 11-13-2025
- Dividend Yield
- KPRX N/A
- AQMS N/A
- EPS Growth
- KPRX N/A
- AQMS N/A
- EPS
- KPRX N/A
- AQMS N/A
- Revenue
- KPRX N/A
- AQMS N/A
- Revenue This Year
- KPRX N/A
- AQMS N/A
- Revenue Next Year
- KPRX N/A
- AQMS $550.00
- P/E Ratio
- KPRX N/A
- AQMS N/A
- Revenue Growth
- KPRX N/A
- AQMS N/A
- 52 Week Low
- KPRX $2.21
- AQMS $3.37
- 52 Week High
- KPRX $4.18
- AQMS $39.40
- Technical
- Relative Strength Index (RSI)
- KPRX 42.35
- AQMS 50.67
- Support Level
- KPRX $2.21
- AQMS $9.00
- Resistance Level
- KPRX $2.80
- AQMS $39.37
- Average True Range (ATR)
- KPRX 0.15
- AQMS 4.57
- MACD
- KPRX -0.03
- AQMS -0.43
- Stochastic Oscillator
- KPRX 41.72
- AQMS 13.28
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.